Business Context and Reporting Period
This Form 8-K filing by Ocular Therapeutix, Inc. (a Delaware corporation) reports a corporate governance event dated September 11, 2015. The report was filed on September 14, 2015, by W. Bradford Smith, Chief Financial Officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the appointment of a new director and associated compensation arrangements.
Material Changes
The primary material change is the election of Jeffrey S. Heier, M.D., to the Board of Directors to fill a vacancy. Dr. Heier was designated as a Class III member, serving until the 2017 annual meeting of stockholders. There are no arrangements or understandings between Dr. Heier and other persons regarding his election, and no transactions requiring disclosure under Item 404(a) of Regulation S-K were identified.
Guidance, Outlook, and Compensation
Dr. Heier will be compensated in the same manner as other non-employee directors. Upon election, he received an option to purchase 11,363 shares of common stock at an exercise price of $16.64 per share. Additionally, Dr. Heier entered into the Company's standard Indemnification Agreement, which may require the Company to indemnify him for expenses, including attorneys' fees, judgments, fines, and settlement amounts incurred in actions arising from his service as a director.
Investor Verification Checklist
- Verify the total number of outstanding shares and the impact of the 11,363 new options on potential dilution.
- Review the Company's proxy statement filed on April 24, 2015, for details on the standard compensation structure for non-employee directors.
- Confirm the terms of the standard Indemnification Agreement filed as Exhibit 10.12 to the Form S-1 (File No. 333-196932).
- Monitor future filings for any changes in the Board composition or additional director appointments.